Search
Search Results
##search.searchResults.foundPlural##
-
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3886PDF: 2682HTML: 1722 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4854PDF: 3991HTML: 384 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
3098PDF: 1374HTML: 2856Figure 1: 239 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2752PDF: 1851HTML: 744 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2518PDF: 2196HTML: 267 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9643PDF: 6370HTML: 88347Fig.1b: 315Fig.1c: 318Fig.2a: 317Fig.2b: 278Fig.4: 344Fig.2c: 302Fig.3: 298Tab.1: 359Tab.2: 330Tab.3: 324Tab.4: 369Fig1a: 312 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2545PDF: 1425HTML: 17253Bassan Fig.1: 190Bassan Fig.2: 296Bassan Fig.4: 181Fig.3: 326 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4520PDF: 2067HTML: 5577Table 1: 319 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1598PDF: 909HTML: 3157 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
6028PDF: 1638HTML: 1690Untitled: 296 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3692PDF: 1392HTML: 2428Fi.1 Gritti.Rambaldi: 278 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3656PDF: 900HTML: 3045Figure 1a and 1b: 227Figure 2: 240Figure 3: 229Figure 4: 222Figure 5: 218Tables 1-5: 195 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3974PDF: 1755HTML: 121 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3991PDF: 1741HTML: 897Figures . Eliassian: 343 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1845PDF: 1182HTML: 201 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
2157PDF: 890HTML: 690 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2781PDF: 1768HTML: 2474Table1: 312 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1522PDF: 669HTML: 4208 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1484PDF: 514HTML: 18650Figure 1: 217Figure 2: 197Figure 3: 219Figure 4: 262Figure 5: 227 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
5054PDF: 1934HTML: 2908Untitled: 349 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2562PDF: 1106HTML: 1684Fig 1: 288Tab I: 271Cover Letter: 287 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1489PDF: 594HTML: 313 -
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1333PDF: 664HTML: 6945 -
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS
1671PDF: 1001HTML: 2019Figure: 238Tables: 243ALL revision 1: 369response to reviewer: 248 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1668PDF: 1362HTML: 548 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1795PDF: 834HTML: 1526 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2377PDF: 953HTML: 391 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1615PDF: 1436HTML: 126







